TAR-200 Monotherapy Displays Early Efficacy in BCG-Unresponsive NMIBC
May 5th 2023Sia Daneshmand, MD, discusses the rationale for investigating TAR-200 for the treatment of patients with Bacillus Calmette-Guérin-unresponsive, high-risk non–muscle-invasive bladder cancer, expands on the preliminary efficacy and safety data from the SunRISe-1 trial, and more.
Read More
Gedatolisib, Fulvestrant, and Palbociclib Triplet Under Investigation in HR+/HER2– Breast Cancer
May 4th 2023The combination of gedatolisib and fulvestrant with or without palbociclib is under evaluation in the phase 3 VIKTORIA-1 trial for the treatment of patients with PIK3CA-mutated or wild-type hormone receptor–positive/HER2-negative breast cancer who have previously progressed on first-line therapy.
Read More
Manali Bhave, MD, discusses the effect of emerging therapies on the treatment landscape for patients with HR-positive, HER2-negative or -low breast cancer, highlighted her stance on sequencing decisions for these patients, and expanded on the additional work being done to optimize treatment sequencing from a growing list of options.
Read More
VT3989 Shows Activity, Tolerability in Mesothelioma and Other NF2-Mutated Solid Tumors
April 26th 2023VT3989, a first-in-class YAP/TEAD inhibitor, showcased durable antitumor activity and tolerability in patients with malignant mesothelioma and other solid tumors harboring NF2 mutations, according to data from a phase 1 trial presented at the 2023 AACR Annual Meeting.
Read More
Furmonertinib Plus Icotinib Elicits Antitumor Activity in EGFR+ NSCLC With CNS Metastases
April 26th 2023First-line treatment with furmonertinib plus icotinib induced responses in patients with EGFR-mutant non–small cell lung cancer. including those with central nervous system metastases, according to data from an ongoing phase 2 trial.
Read More
Subgroup Analysis Shows Consistent Benefit for Dostarlimab Plus Chemo in Nonsquamous NSCLC
April 24th 2023Overall response rates were similar across subgroups of patients with nonsquamous non–small cell lung cancer for the combinations of dostarlimab-gxly plus chemotherapy and pembrolizumab plus chemotherapy, and responses numerically favored the dostarlimab-based combination in most subgroups, according to a subgroup analysis of the phase 2 PERLA trial.
Read More
Tucatinib/Trastuzumab Approval Highlights Expansion of Tailored Therapies in HER2+ CRC
April 21st 2023John L. Hays, MD, PhD, discusses the importance of tailoring therapies for patients with CRC who express HER2 or have other actionable targets, the need to develop optimal sequences for local and systemic therapy in CRC, and key updates in hepatocellular carcinoma and pancreatic cancer.
Read More
Post-Hoc Analysis Supports Adjuvant Pembrolizumab in ccRCC at Increased Risk of Recurrence
April 19th 2023Adjuvant pembrolizumab prolonged disease-free survival and distant metastasis–free survival vs placebo in patients with clear cell renal cell carcinoma at increased risk of recurrence after nephrectomy, irrespective of UCLA Integrated Staging System risk category and disease stage.
Read More
Terence Friedlander, MD, discusses the significance of the FDA approval of enfortumab vedotin combined with pembrolizumab for patients with locally advanced or metastatic urothelial carcinoma, and expands on the data from the EV-103/KEYNOTE-869 trial that supported the approval.
Read More
Ganitumab Plus Interval-Compressed Chemotherapy Fails to Improve EFS in Metastatic Ewing Sarcoma
April 11th 2023R. Lor Randall, MD, FACS, expands on data from a phase 3 trial evaluating the addition of ganitumab to standard-of-care, interval-compressed chemotherapy, the implications of these results, and how the study could help inform future trials exploring other targeted therapies for the treatment of patients with metastatic Ewing sarcoma.
Read More
BXCL701 Plus Pembrolizumab Elicits Durable Responses in Small Cell Neuroendocrine mCRPC
April 10th 2023The combination of BXCL701 and pembrolizumab produced durable responses in patients with platinum-resistant small cell neuroendocrine carcinoma metastatic castration-resistant prostate cancer, according to data from a phase 2a trial presented at the 2023 Genitourinary Cancers Symposium.
Read More
Novel Tucatinib-based Regimens Highlight Ongoing Research in HER2+ Breast Cancer
April 10th 2023Jennifer M. Matro, MD, discusses the real-world implications and uptake of the HER2CLIMB regimen, other trials investigating tucatinib-based regimens in HER2-positive metastatic breast cancer, and how approaches differ between early-stage and metastatic hormone receptor–positive/HER2-negative breast cancer.
Read More
Teclistamab Leads Ongoing Emergence of Bispecific Antibodies in Multiple Myeloma
April 4th 2023Jeffrey Zonder, MD, discussed the ongoing development of other BCMA-targeted and non–BCMA targeted bispecific antibodies, toxicity management for these agents, how to navigate treatment decisions for patients eligible for CAR T-cell therapy, and ongoing research in multiple myeloma at the Barbara Ann Karmanos Cancer Institute.
Read More
Teclistamab, Other BCMA-Targeted Agents Represent New Options in Relapsed/Refractory Myeloma
April 1st 2023Andrew Kin, MD, expands on the ways BCMA-targeted therapies that are currently available and under development have shifted the treatment landscape for relapsed/refractory multiple myeloma, the implications of the approval of teclistamab, and the limitations that still exist for using BCMA-targeted agents.
Read More
Implementation of Early End Points Could Represent New Standard for Breast Cancer Clinical Trials
March 30th 2023Laura J. Esserman, MD, MBA, discusses the effect early end points could have for clinical trials in breast cancer, how these end points could help usher in more individually tailored treatment options based on an individual patient’s disease and response, and how early end points have been used in the ongoing phase 2 I-SPY 2 trial.
Read More
Multiple Factors Need to Be Addressed to Improve Late Mortality for Survivors of Childhood Cancer
March 24th 2023Matthew J. Ehrhardt, MD, MS, discusses the importance of taking a multifactorial approach to improve long-term outcomes for survivors of childhood cancer, and expands on the findings from the study of the factors associated with risk of late mortality.
Read More
Nationwide Initiative Aims to Address Disparities in Early-Phase Cancer Clinical Trials
March 23rd 2023To expand access to cancer care and research, Stand Up To Cancer® has launched a 4-team initiative across the United States designed to fill in these gaps in care and remove barriers to entry.
Read More
Improved Understanding of Biomarkers in Tumor Microenvironment Key for Treatment Decisions in NSCLC
March 23rd 2023Brian S. Henick, MD, discusses the importance of expanding on the current knowledge of biomarkers and the tumor microenvironment to enhance treatment approaches for patients with non–small cell lung cancer.
Read More
First-line ASCT Consolidation Confers Real-world Survival Benefit in Mantle Cell Lymphoma
March 20th 2023Consolidative autologous stem cell transplant was associated with a statistically significant lower overall mortality risk and higher overall survival probability in patients with mantle cell lymphoma vs those who did not receive consolidation.
Read More
ASCT Following First Complete Remission Does Not Improve Real-World Survival in Mantle Cell Lymphoma
March 19th 2023First-line consolidative autologous stem cell transplant following first complete remission, with or without maintenance rituximab, did not result in improved overall survival for patients with mantle cell lymphoma.
Read More
Maintenance Avelumab Plus Lurbinectedin Under Investigation in Metastatic Urothelial Carcinoma
March 17th 2023Investigators are assessing the combination of avelumab and lurbinectedin as maintenance therapy for patients with metastatic urothelial carcinoma who achieve a response or stable disease following first-line, platinum-based chemotherapy in a single-arm phase 2 trial.
Read More
Pembrolizumab Data Highlight Potential for Adjuvant Immunotherapy in RCC
March 17th 2023Christopher W. Ryan, MD, discusses the role of adjuvant pembrolizumab in renal cell carcinoma, the use of immunotherapy-based combinations in the frontline setting for metastatic renal cell carcinoma, and key data presented at the 2023 Genitourinary Cancers Symposium in bladder cancer and prostate cancer.
Read More
Siltuximab Resolves CRS/ICANS After CAR T-cell Therapy for Hematologic Malignancies
March 16th 2023Mayur Narkhede, MD, discusses the early findings for the use of siltuximab to manage cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome in patients following CAR T-cell therapy and expands on the next steps for investigating this agent during the phase 2 trial.
Read More
AB011 Plus CAPOX Demonstrates Preliminary Safety, Efficacy in Advanced Gastric/GEJ Cancer
March 13th 2023The combination of AB011 and capecitabine/oxaliplatin was found to have a manageable safety profile and to showcase early clinical benefit when used as first-line treatment in patients with gastric cancer or gastroesophageal junction adenocarcinoma.
Read More